Skip to content

Brazilian Journal of Psychiatry

ISSN 1516-4446

12 papers in the library · 1,011 citations · publishing 2008-2026

Papers

Sort Most recent Most cited

Prophylactic efficacy of cannabidiol and sodium nitroprusside in a ketamine model of schizophrenia: sex-dependent effects on positive-like and cognitive impairments

Brazilian Journal of Psychiatry June 16, 2026 Daniel B.a. Prado, Matheus T. Rossignoli, Rafael N. Ruggiero et al.

Objective: Current treatments for schizophrenia (SZ) are often not effective for all symptoms, with sex-dependent effects poorly understood. Cannabidiol (CBD) and sodium nitroprusside (SNP) have emerged as potential prophylactic options. We evaluated their efficacy in preventing positive, negative, and cognitive deficits in a ketamine (KET) rodent model of SZ in both sexes. Methods: Wistar rats...

Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study

Brazilian Journal of Psychiatry 2025 David S. Mathai, Jill O. Robinson, Kevin Wagner et al. 1 citation

OBJECTIVE: Despite growing research on the potential mental health benefits of psychedelics, there has been limited study of these drugs in populations with obsessive-compulsive disorder (OCD) and with Hispanic and Latin American (H/L) ancestry. METHODS: Demographic and clinical assessments were conducted as part of the Latin American Trans-ancestry Initiative for OCD genomics (LATINO) Study in...

Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial

Brazilian Journal of Psychiatry February 18, 2021 Mara C. Guimarães, Tiago M. Guimarães, Jaime E. C. Hallak et al. 41 citations

OBJECTIVE: Major depressive disorder (MDD) is related to glutamatergic dysfunction. Antagonists of glutamatergic N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have antidepressant properties. Nitrous oxide (N2O) is also a NMDAR antagonist. Thus, this study aimed to evaluate the effects of augmenting antidepressant treatment with N2O. METHODS: This double blind, placebo-controlled...

Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects

Brazilian Journal of Psychiatry October 30, 2020 Ícaro Durante, Rafael G. Dos Santos, José Carlos Bouso et al. 49 citations

A minority of participants reported being very negatively affected by persistent adverse effects. Psychiatric medication use while participating in ayahuasca rituals was not associated with increased adverse effects. For the most part, the institution's practices seem sufficient to prevent exacerbated reactions. Future studies may focus on negatively affected users.

The pharmacological interaction of compounds in ayahuasca: a systematic review

Brazilian Journal of Psychiatry July 3, 2020 Simon Ruffell, Nige Netzband, Catherine Bird et al. 43 citations

Ayahuasca is a South American psychoactive plant brew used as traditional medicine in spiritual and in cultural rituals. This is a review of the current understanding about the pharmacological mechanisms that may be interacting in ayahuasca. Searches were performed using PubMed, PsycINFO, and Web of Science databases and 16 papers were selected. As hypothesized, the primary narrative in...

Acute effects of ayahuasca in a juvenile non-human primate model of depression

Brazilian Journal of Psychiatry November 21, 2018 Flávia S. Da Silva, Erick Allan Dos Santos Silva, Geovan Menezes de Sousa et al. 46 citations

OBJECTIVE: The incidence rate of major depression in adolescents reaches approximately 14%. This disorder is usually recurrent, without remission of symptoms even after pharmacological treatment, and persists throughout adult life. Since the effects of antidepressants take approximately 2 weeks to begin, new pharmacological therapies are under continuous exploration. Recent evidence suggests...

Conceptions and practices of an integrative treatment for substance use disorders involving Amazonian medicine: traditional healers’ perspectives

Brazilian Journal of Psychiatry December 16, 2017 Ilana Berlowitz, Christian Ghasarian, Heinrich Walt et al. 39 citations

OBJECTIVE: The harmful use of psychoactive substances represents one of today's largest public health problems. Yet, in spite of its global relevance, current treatment for substance use disorders (SUDs) is still not entirely successful. The purpose of this study was to investigate alternative treatments and conceptions from traditional Amazonian medicine adapted to SUDs. METHODS: We conducted...

Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies

Brazilian Journal of Psychiatry March 1, 2016 Rafael G. Dos Santos, Flávia de Lima Osório, José Alexandre S. Crippa et al. 158 citations

Considering the need for new drugs that produce fewer adverse effects and are more effective in reducing anxiety and depression symptomatology, the described effects of ayahuasca and its alkaloids should be further investigated.

Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)

Brazilian Journal of Psychiatry March 1, 2010 Jaime E. C. Hallak, João Paulo Machado‐de‐Sousa, José Alexandre S. Crippa et al. 122 citations

OBJECTIVE: The last decade has seen increasing evidence of dysfunctions in the endogenous cannabinoid system in schizophrenia and of its relationship with the typical cognitive impairment of the disorder. Studies in animal models, healthy volunteers, and psychotic patients clearly suggest an antipsychotic-like effect of cannabidiol. This study investigated the effects of cannabidiol on...

Revisão: funcionamento executivo e uso de maconha

Brazilian Journal of Psychiatry March 1, 2008 Priscila Previato Almeida, Maria Alice Fontes Pinto Novaes, Rodrigo A. Bressan et al. 24 citations

OBJECTIVE: Cannabis is the most used illicit drug worldwide, however only a few studies have examined cognitive deficits related to its use. Clinical manifestations associated with those deficits include a motivational syndrome, impairment in cognitive flexibility, inattention, deficits in abstract reasoning and concept formation, aspects intimately related to the executive functions, which...